All In Biotech

Drug Trial Radar · NCT07229937

A Phase II Study To Evaluate the Efficacy And Safety Of HRS-1301 In Participants With Dyslipidemia

A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of HRS-1301 in Participants With Dyslipidemia

Last checked: Nov 20, 2026Latest source record: Dec 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 189 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

189

Planned (sponsor's estimate)

Start

Nov 25, 2025

Primary completion

Aug 2026

Study completion Aug 2026

Sponsor

Sponsor type
Industry
First posted
Nov 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to explore the reasonable dosage of HRS-1301 in participants with dyslipidemia. The efficacy and safety of HRS-1301 will be evaluated after 12-weeks treatment.

Conditions

  • Hyperlipidemia

Interventions

  • HRS-1301Drug

    HRS-1301 Dose 1,oral

  • HRS-1301Drug

    HRS-1301 Dose 2,oral

  • HRS-1301Drug

    HRS-1301 Dose 3,oral

  • HRS-1301Drug

    HRS-1301 Dose 4,oral

  • PlaceboDrug

    Placebo,oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage change in LDL-C relative to baselineTime frame: at 12 weeks of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The 2nd Affiliated Hospital of Harbin

    Harbin, Heilongjiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.